BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Pathophysiol. Mar 22, 2026; 17(1): 115307
Published online Mar 22, 2026. doi: 10.4291/wjgp.v17.i1.115307
From esophagus to colon: A narrative review of eosinophilic gastrointestinal disorders
Abeer Qasim, George S Zacharia, FNU Veena, Sameer D Kandhi, Harish Patel
Abeer Qasim, Sameer D Kandhi, Harish Patel, Department of Gastroenterology, BronxCare Health System, Bronx, NY 10457, United States
George S Zacharia, FNU Veena, Department of Internal Medicine, BronxCare Health System, Bronx, NY 10457, United States
Co-first authors: Abeer Qasim and George S Zacharia.
Author contributions: Qasim A and Kandhi SD contributed to conceptualization, literature search and data acquisition; Qasim A and Zacharia GS contributed to data analysis and interpretation, have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the paper; Qasim A, Zacharia GS, Veena F contributed to manuscript drafting, critical revision of the manuscript for important intellectual content; Patel H final approval of the version to be published; all authors agree to be accountable for all aspects of the work and ensure accuracy and integrity of the content.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Corresponding author: George S Zacharia, DM, MD, Academic Fellow, Department of Internal Medicine, BronxCare Health System, 1650 Grand Concourse, Bronx, NY 10457, United States. george.lenx@yahoo.com
Received: October 16, 2025
Revised: December 17, 2025
Accepted: January 27, 2026
Published online: March 22, 2026
Processing time: 157 Days and 16.8 Hours
Abstract

Eosinophilic gastrointestinal disorders (EGID) are a heterogeneous group of chronic diseases characterized by excessive infiltration of eosinophils in the gastrointestinal tract in the absence of identifiable secondary causes. Primary EGID includes eosinophilic esophagitis, eosinophilic gastroenteritis, and eosinophilic colitis. The purpose of this review is to provide a concise overview of the current understanding and management of EGID. The published data were extracted by a comprehensive literature search in PubMed/MEDLINE with keywords related to EGID. The retrieved data were analyzed and synthesized into a narrative review emphasizing clinical features, evaluation, and treatment strategies. A brief outline of the etiopathogenesis of the disease was also derived from the published literature. EGID, especially esophagitis, has demonstrated an increasing global prevalence, more frequent in men and those with other atopic conditions. The etiology of EGID remains poorly understood, though allergic mechanisms are heavily implicated. Sensitization to foods or aeroallergens is common, yet only a minority experiences food-induced anaphylaxis, suggesting distinct non-IgE-mediated pathways in disease pathogenesis. Genetic factors and dysregulation in gene expression related to eosinophil recruitment, notably eotaxin-3, are implicated as well. The clinical manifestations vary according to the site of gastrointestinal tract involvement. The diagnosis relies on endoscopic biopsies to reveal the tissue eosinophilia. The treatment strategies include dietary modification or elimination diets, steroids and other anti-allergic medications, proton pump inhibitors, and monoclonal antibodies targeting eosinophils or key inflammatory cytokines. Therapeutic endoscopic procedures might benefit patients with strictures, particularly those involving esophagus.

Keywords: Eosinophilic; Gastrointestinal diseases; Esophagitis; Gastritis; Gastroenteritis; Colitis; Proton pump inhibitors

Core Tip: Eosinophilic gastrointestinal disorders encompass a spectrum of chronic, immune-mediated conditions characterized by eosinophilic infiltration of the gastrointestinal tract in the absence of secondary causes. Despite its increasing prevalence, significant gaps remain in awareness, diagnosis, and treatment of the disease. The diagnosis mandates demonstration of tissue eosinophilia, typically on gastrointestinal endoscopic biopsies, together with exclusion of secondary causes. The treatment involves dietary modifications, corticosteroids, proton pump inhibitors, and emerging biologics targeting key cytokine pathways. The lack of standardized guidelines emphasizes the need for multidisciplinary care and further research to refine diagnostic thresholds and optimize treatment strategies.